Home | Contact us | Disclaimer
MEDIA center
Transition Therapeutics Corporate Presentation


Transition Therapeutics Research Day 2014


ELND005 Phase II Clinical Study Data in Alzheimer's Disease

  • Safety and Efficacy Results of a Phase 2 Randomized, Placebo-Controlled, Dose-Ranging Study of ELND005 (Scyllo-inositol) in Mild to Moderate Alzheimer’s Disease
    Stephen Salloway et al.
    [Original ICAD poster] [Reformatted version]
  • Imaging & Cerebrospinal Fluid Biomarker Results of a Phase 2 Dose-Ranging Study of ELND005 (Scyllo-inositol) in Mild/Moderate AD
    Dr. Anton Porsteinson, William B and Sheila Konar on behalf of ELND005-AD201 investigators
    [ICAD presentation]
  • Population Pharmacokinetic Analysis of Plasma, Cerebrospinal Fluid, and Brain ELND005 in Patients with Mild to Moderate Alzheimer’s Disease
    Earvin Liang et al.
    [Original ICAD poster] [Reformatted version]
  • A Phase 2 randomized trial of ELND005, scyllo-inositol, in mild-moderate Alzheimer’s disease
    Salloway et al., Neurology, September 27, 2011 issue
    [Link to Neurology]

© 2015 Transition Therapeutics Inc.